Compared to these antigens, PpiA displays comparable epitope accessibility and immunogenicity, particularly through its ability to induce potential CD8+ and CD4+ T-cell responses, further supporting its candidacy as a novel TB vaccine target. The gene discussed is PPIA; the disease is tuberculosis.